SCHEMBL776183

SCHEMBL776183

[O-][S+](c1ccc(F)cc1)c1ccc(F)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.38
CA2 P00918 4/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
ACHE P22303 1/20 0.38
IDO1 P14902 1/20 0.33
ORAI1 Q96D31 1/20 0.33
ORAI2 Q96SN7 1/20 0.33
ORAI3 Q9BRQ5 1/20 0.33
TRPV6 Q9H1D0 1/20 0.33
CES2 O00748 1/20 0.33
CES1 P23141 1/20 0.33
LOXL2 Q9Y4K0 1/20 0.33
MMP1 P03956 1/20 0.32
MMP2 P08253 1/20 0.32
MMP9 P14780 1/20 0.32
MMP8 P22894 1/20 0.32
MMP13 P45452 1/20 0.32
TAAR1 Q96RJ0 1/20 0.31
NFE2L2 Q16236 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11980108 0.89 NFE2L2 (0.41) CA1CA2CA7CA9ACHE
SCHEMBL776470 0.89 NFE2L2 (0.41) CA1CA2CA7CA9ACHE
SCHEMBL3155473 0.87 ACHE (0.62) ACHENFE2L2
SCHEMBL7937426 0.87 MAPT (0.41)
SCHEMBL15910197 0.85 HSPB1 (0.48) MMP1MMP2MMP9MMP13
SCHEMBL28464325 0.85 IDO1 (0.41) IDO1LOXL2TAAR1
SCHEMBL19570743 0.85 USP2 (0.42) TAAR1
SCHEMBL7938378 0.83 PAX8 (0.41) ORAI1ORAI2ORAI3TRPV6CES2
SCHEMBL7938269 0.83 TSHR (0.37)
SCHEMBL7937373 0.83 ALDH1A1 (0.39) ACHENFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230132782-A1 METHOD AND COMPOSITIONS FOR TREATING, PREVENTING OR LIMITING THE OCCURRENCE OF VIRAL INFECTION GLOBAL BIOLIFE INC. 2023-05-04 US claimed
EP-4121040-A1 METHOD AND COMPOSITIONS FOR TREATING, PREVENTING OR LIMITING THE OCCURRENCE OF VIRAL INFECTION Global Biolife Inc. (US) 2023-01-25 EP claimed
WO-2021188520-A1 METHOD AND COMPOSITIONS FOR TREATING, PREVENTING OR LIMITING THE OCCURRENCE OF VIRAL INFECTION GLOBAL BIOLIFE INC. (US) 2021-09-23 WO claimed
CN-109081920-A A kind of performed polymer containing sulfoxide structure and preparation method thereof and a kind of advanced composite material 吉林大学 2018-12-25 CN claimed
US-9469604-B2 Method of manufacturing sulfonium salt TOYO GOSEI CO., LTD. (JP) 2016-10-18 US claimed
US-8034838-B2 Composition and method for the treatment of neurological disorders GLOBAL BIOLIFE, INC. 2011-10-11 US claimed
US-20090298932-A1 COMPOSITION AND METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS GLOBAL BIOLIFE, INC. 2009-12-03 US claimed
JP-11269169-A None JP disclosed
JP-8165290-A None JP disclosed
CN-119504523-A Preparation method of fluorine-containing phenyl sulfoxide compound 苏州源起材料科技有限公司 2025-02-25 CN disclosed
US-12100809-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-24 US disclosed
US-20230132782-A1 METHOD AND COMPOSITIONS FOR TREATING, PREVENTING OR LIMITING THE OCCURRENCE OF VIRAL INFECTION GLOBAL BIOLIFE INC. 2023-05-04 US disclosed
US-11609495-B2 Radiation-sensitive resin composition and resist pattern-forming method JSR CORPORATION (JP) 2023-03-21 US disclosed
EP-0143407-B1 PROCESS FOR PREPARING AROMATIC POLYETHERS HOECHST AKTIENGESELLSCHAFT (DE) 1986-11-12 EP disclosed
EP-0067850-B1 BLENDS OF COPOLY (ESTER-CARBONATE) WITH POLYSULFONE GENERAL ELECTRIC COMPANY (US) 1985-11-13 EP disclosed
EP-0143407-A2 Process for preparing aromatic polyethers HOECHST AKTIENGESELLSCHAFT (DE) 1985-06-05 EP disclosed
EP-0067850-A4 BLENDS OF COPOLY (ESTER-CARBONATE) WITH POLYSULFONE. GEN ELECTRIC (US) 1983-04-18 EP disclosed
EP-0067850-A1 BLENDS OF COPOLY (ESTER-CARBONATE) WITH POLYSULFONE. GEN ELECTRIC (US) 1982-12-29 EP disclosed
US-4358569-A FLAME RESISTANT THERMOPLASTIC MOLDING MATERIAL OF GOOD IMPACT STRENGTH GENERAL ELECTRIC COMPANY (US) 1982-11-09 US disclosed
WO-1982002401-A1 BLENDS OF COPOLYESTER-CARBONATE WITH POLYSULFONE GEN ELECTRIC (US) 1982-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230132782-A1 METHOD AND COMPOSITIONS FOR TREATING, PREVENTING OR LIMITING THE OCCURRENCE OF VIRAL INFECTION ACE2, ACE, TMPRSS2 CA1 2593/4885CA2 494/4885CA7 277/4885
US-11609495-B2 Radiation-sensitive resin composition and resist pattern-forming method RER1, RAD51, AFF1 CA1 1717/4885CA2 3709/4885CA7 2047/4885
US-20090298932-A1 COMPOSITION AND METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BACE1, APP, BACE2 CA1 1139/4885CA2 3585/4885CA7 4501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.